Dengue virus (DENV) is one of the major infectious diseases in tropical regions and approximately half of the world population is at risk of infection. Vaccines would offer an effective control measure against this disease. We previously reported on the utility of marmosets as an animal model for studying primary and secondary dengue infections. Infected marmosets consistently develop viraemia and antibody kinetics that reflect those of patients with dengue. Thus, it is important to determine the utility of marmosets as an animal model for demonstrating vaccine efficacy. In this study, marmosets were inoculated with candidate vaccine and parent strains and challenged with a clinical DENV strain. The viraemia and antibody kinetics in these marmosets were determined. Marmosets consistently develop lower viraemia with an attenuated vaccine strain. During secondary challenge, the IgM response was delayed, whereas the IgG levels rose rapidly, indicating a secondary antibody response. The neutralizing activities against the homotypic serotype were high; all marmosets were protected against viraemia following secondary inoculation. The viraemia markers and antibody responses were consistent with those of human DENV infection and vaccinees. These results demonstrate the utility of marmosets as an animal model for the study of vaccine efficacy.
INTRODUCTION
Dengue virus (DENV), a serious global health threat, infects approximately 400 million people and causes 25 000 deaths, mostly in children, each year [1, 2] . Dengue has increased by more than 30-fold in the last 50 years, and it is projected that at least 4 billion people will be at risk of DENV infection annually [3] . Thus, effective vaccines will be important for dengue disease control.
Robust animal models to measure the efficacy and safety of candidate DENV vaccines will be important to facilitate the development of effective vaccines [4] . Rodent models have been shown to be useful for the initial efficacy and safety testing of vaccines and therapeutics owing to their ease of handling and availability [5] [6] [7] [8] [9] . In contrast to wild-type mice, immunocompromised mice develop overt clinical signs during DENV challenge [10] [11] [12] . However, in terms of suitability for subsequent vaccine efficacy tests, there remains a need to refine the immunocompromised model to compensate for the lack of immune regulators, differential display in susceptibility between adapted strains and clinical isolates and age-associated susceptibility to the virus. Non-human primates (NHPs), such as cynomolgus macaques and rhesus monkeys, have been useful for the evaluation of candidate vaccines owing to the close genetic proximity and similar immune systems of humans and primates [13] [14] [15] [16] [17] [18] [19] [20] [21] . Robust immune responses have been induced in vaccinated macaques, although there is a lack of consistency in the viraemia in some NHP models [22] . Due to safety and efficacy concerns, novel approaches using other primate models that consistently develop assessable markers, including high levels of viraemia and antibody responses that reflect those of patients with dengue, are required to improve vaccine efficacy studies. An ideal animal model for vaccine efficacy studies should (1) possess close genetic proximity to humans, (2) develop clinical signs, including high levels of viraemia upon challenge with clinical virus isolates, and (3) demonstrate protective immunity that reflects that of human patients with dengue. We previously established a common marmoset model (Callithrix jacchus) for DENV infection [23, 24] . Marmosets consistently develop high levels of viraemia during primary and secondary infection, and have demonstrated immune response patterns that are similar to those of human DENV infection [24, 25] . However, the utility of this model in vaccine efficacy studies has not yet been assessed. In the present study, we evaluated the marmoset model as an animal model for vaccine development studies using a live-attenuated vaccine for dengue that had been developed by serial passage of parent DENV strains in a primary dog kidney (PDK) cell line [26] [27] [28] [29] . Vaccine candidates, including live-attenuated vaccine, tetravalent chimeric vaccine and subunit vaccine, have been developed and evaluated for efficacy using mice and macaque dengue disease models [30] [31] [32] [33] [34] [35] [36] . Here, marmosets were first immunized with a DENV-1 and DENV-2 candidate vaccine, and then challenged with clinical DENV strains of the same serotype. The viraemia and immunogenicity after vaccination and challenge were determined in these marmosets. Our results indicate that the viraemia and antibody responses of vaccinated marmosets closely reflect those of humans, and suggest that the marmoset model is potentially useful for DENV vaccine efficacy studies.
RESULTS

Absence of clinical signs in DENV-vaccinated marmosets
To detect the associated clinical signs, all marmosets were evaluated daily for general conditions, including activity levels, appetite and diarrhoea. None of the eight marmosets (groups A and D) exhibited clinical signs indicating DENVassociated disease, including rash, purpura, weight loss, leukopenia, or thrombocytopenia upon immunization with the DENV-1 and DENV-2 vaccine strains in experiment 1. Of the four marmosets (E1-E4) that were inoculated with the parent DENV-2 strain, three (3/4, 75 %) exhibited leukopenia and thrombocytopenia on days 4 and 7 after inoculation (data not shown).
DENV viraemia and NS1 antigenemia levels in marmosets
The first immunization with 10 4 p.f.u. of the DENV-1 and DENV-2 vaccine strains resulted in moderate levels of plasma viral RNA (vRNA) of 1.5 to 3.8 log 10 genome copies ml -1 on days 2 to 10 after inoculation. However, vRNA was absent in all four marmosets by day 14 after inoculation.
Because plaque formation was not observed in the isolated DENV-1 and DENV-2 parent and vaccine strains from days 2 to 14 after inoculation, the levels of viraemia could not be expressed as p.f.u. The absence of plaque formation could be due to the low sensitivity of the plaque detection method when using BHK cells. During homotypic challenge with clinically isolated DENV-1 and DENV-2 strains, none of the vaccinated marmosets (groups A and D) developed viraemia or NS1 antigenemia (Tables 1 and 2 , Fig. 1 ). Similarly, none of the marmosets previously inoculated with the parent DENV strain developed viraemia or NS1 antigenemia (groups B and E). In comparison, upon challenge with the same clinical isolates, naïve marmosets developed both viraemia and NS1 antigenemia (groups C and F). The results demonstrate that prior immunization with vaccine or parent strains induced immunity to secondary DENV challenge in the marmoset model, consistent with results obtained in vaccinees [37] .
Induction of robust immunity with second inoculation after vaccination Plasma samples from all marmosets were tested for DENVspecific IgM and IgG antibodies. Most marmosets demonstrated IgM antibodies by day 7 after first immunization with vaccine and parent DENV strains (Tables 3 and 6 , Fig. 1 ). With the exception of marmoset A3, seven of the eight marmosets with prior exposure to the DENV vaccine strain demonstrated IgM antibodies during challenge with clinical strains. By comparison, in six of the eight marmosets previously inoculated with the DENV parent strain IgM antibodies were not detected.
IgG antibodies were first detected on day 14 after inoculation with DENV vaccine and parent strains (groups A, B, D and E; Table 4 ). IgG antibodies remained in these groups prior to challenge with a clinical isolate. In these 16 marmosets (groups A, B, D and E) the levels of IgG antibodies increased from day 7 after the second inoculation to higher levels than those of the first inoculation at 2 weeks after inoculation (P<0.001). Reflecting the IgG patterns, all eight marmosets that were inoculated with DENV vaccine strain seroconverted and developed neutralizing antibodies by day 15 (plaque-reduction neutralizing test, PRNT 50 =10-80) after the first inoculation and exhibited high levels of neutralizing antibodies (PRNT 50 =640-10240) after the second inoculation (groups A and D; Tables 5 and 6 ). Similar patterns were observed in marmosets initially inoculated with the parent strain (PRNT 50 =10-80) and challenged with a clinical strain (PRNT 50 =640-2560).
These results indicate that specific B cell and T cell memories are induced and maintained by immunization with the candidate vaccines (groups A and D), and also suggest that although viraemia was absent after challenge with clinical isolates, immunization with the candidate vaccines does not ensure sterile immunity. 
DISCUSSION
We previously confirmed the utility of marmosets for studies on dengue primary and secondary infections [23, 24] . To evaluate the utility of this model, a DENV-1 and DENV-2 live-attenuated candidate vaccine was chosen. While the degree of attenuation is determined by the difference between the levels of viraemia for the parent and the attenuated candidate vaccine, because a lower level of viraemia is associated with reduced clinical symptoms, a candidate vaccine is selected based on the attributes of 
-, viraemia below detection levels; ND, not determined due to limited amount of sample available; NA, no samples collected. Due to accidental death, no samples were collected from marmoset B3 from day 4 of secondary inoculation.
lowest reactogenicity and highest immunogenicity [38] . Thus, the markers to characterize attenuation include those of reduced viral replication in comparison with the parent DENV strains. Previously, live-attenuated candidate vaccines have demonstrated lower viraemia in both vaccinees and macaque models [32, 39, 40] . The candidate vaccine strain tested in this study was also associated with decreased viraemia levels in macaques [29, 41] . Accordingly, infection with attenuated vaccine strains resulted in a 10Â lower peak vRNA titre (mean=3.75±0.48 log 10 genome copies ml
À1
) as compared to inoculation with parent strains (mean=4.73 ±0.40 log 10 genome copies ml À1 ). Remarkably, the peak NS1 antigenemia levels were also significantly lower in marmosets that were inoculated with vaccine strains [mean positive/negative (P/N) ratio=6.3±5.3] as compared to parent strains (mean P/N ratio=25.0±23.7; P=0.037). Because marmosets (1) consistently demonstrated high levels of viraemia upon DENV challenge (up to 10 7 genome copies ml À1 ), and (2) showed lower peak viraemia and antigenemia during challenge with attenuated vaccine strains, the results suggest the suitability of marmosets as an animal model for vaccine studies. A previous study reported that marmosets also exhibit high levels of viraemia upon infection with all four DENV serotypes [23] . The next step is to further expand the evaluation of marmosets using monovalent candidate vaccines and tetravalent combinations and formulations.
Clinical trials of the vaccine candidate have demonstrated that live-attenuated vaccine is immunogenic in humans [26, 28, 42] . In our previous studies, we demonstrated that IgM and IgG antibody responses in marmosets during primary and secondary infection mimic the antibody responses observed in human DENV infection [23, 24] . In the present study, IgM antibodies were detected prior to IgG antibodies during primary inoculation with vaccine and parent strains. In contrast, IgG antibodies and neutralizing antibodies were detected prior to secondary challenge (day 0), and the antibody titres rose rapidly from day 4 of challenge. These results suggest that antibodies persisted for at least 9 months after vaccine strain challenge, and concur with those of clinical studies [28] .
Of the eight marmosets previously inoculated with the dengue vaccine strain (DENV-1, DENV-2), seven marmosets demonstrated transient vRNA in plasma samples. However, infectious virus particles and NS1 antigenemia were absent in all eight marmosets (<200 p.f.u. ml
). Because NS1 antigen is an important component of the viral replication mechanism [43, 44] , the absence of NS1 antigenemia in these seven marmosets suggests possible defective NS1 antigen secretion due to attenuation, leading to limited viral propagation [45, 46] . Additionally, inoculated virus could potentially be, in part, a source of viral genomic material during virus clearance. In contrast, reduced viraemia has been associated with reduced immunogenicity [38] . Thus, the results suggest that although there was protection against viraemia, sterile immunity was not established in vaccinated marmosets that demonstrated limited levels of anti-DENV IgM antibodies during secondary DENV challenge. Similarly, while sterile immunity was absent in some macaques inoculated with a DENV-2 PDK-53-based tetravalent formulation [47] , further studies would address the optimal inoculation dosage, dosing schedule and dose numbers that would be needed to provide longterm protection.
Protection against dengue is mediated by both humoral and cell-mediated immunity. While the humoral immune response is primarily mediated by neutralizing antibodies cross-reacting with structural proteins, cellular immune response targets the non-structural proteins of DENV [48, 49] . Antibodies are hypothesized to play a central role in offering long-term protection against infection with the same serotype. It is known that high titres of antibodies are induced by the previous infecting serotype. During secondary inoculation, all previously vaccinated marmosets demonstrated high titres of neutralizing antibodies. The marmosets were also protected against the challenge with the same serotype. The results demonstrated the consistency of neutralizing antibody responses in marmosets with those of DENV vaccine trials in humans [50] [51] [52] [53] [54] [55] . It is known that T-cells are associated with protection against DENV infection. Because the TDV candidate vaccine carries a DENV non-structural protein backbone, the candidate vaccine also induces a cell-mediated immune response to non-structural proteins [56] . The rapid increase in the neutralizing antibody levels in the present study indicates that high levels of memory T-and B-cells were induced and maintained in the marmoset model. Given that the marmoset model is a useful model in studies of cellmediated immune response during viral infection [57] , further manipulations of the model would address the role of cell-mediated immunity in dengue vaccine-induced protection.
Dengue vaccine development has progressed greatly with the development of a tetravalent vaccine [58, 59] . Considering the global burden of the disease, vaccines that address efficacy and safety concerns are urgently needed [60] . Characterization of animal models that can be used to test the most relevant markers of immunogenicity, safety and protective efficacy of dengue vaccine candidates holds the key to future vaccine development research. In this context, using a candidate dengue vaccine we demonstrated that marmosets consistently demonstrate viraemia and antibody response patterns that reflect those of DENV patients and vaccinees. The demonstration of these assessable markers for the immunogenicity, safety and protective efficacy of a dengue vaccine candidate in marmosets highlights the utility of this animal model for dengue vaccine development.
METHODS
Ethics statement
The common marmosets (Callithrix jacchus) used in this study were bred for research purposes and were a donation from CLEA Japan, Inc. All animals were housed at the Division of Experimental Animal Research, National Institute of Infectious Diseases (NIID) in Tokyo, Japan. The NIID facilities comply with the Japanese regulations on animal experiments, namely the Law for the Humane Treatment and Management of Animals (law no. 105, Ministry of the Environment, Japan), Standards Relating to the Care and Management of Laboratory Animals and Relief of Pain (notice no. 88 of the Ministry of the strains, respectively) and challenged with clinically isolated DENV of the same serotypes at the same period as the vaccine group. DENV-naïve controls (groups C and F) were used in the second inoculation experiment as a control group (DENV-1 and DENV-2 inoculation). (i) NS1 antigenemia, (ii, iii) anti-DENV IgM and IgG antibody levels, and (iv) viral RNA levels were determined in all marmoset groups. Circles indicate marmosets that were inoculated with the vaccine strains (groups A and D), boxes indicate marmosets inoculated with parent strains (groups B and E) and crosses indicate naïve marmosets (groups C and F). First inoculation is indicated by open markers and second inoculation is indicated by closed markers.
Environment, Japan) and Guidelines for Proper Conduct of Animal Experiments Care and Management Standards (Science Council of Japan).
The animals were housed singly at 27±2 C in 50 ±10 % humidity with a 12 h light-dark cycle (lighting from 7 : 00 to 19 : 00) at the Division of Experimental Animal Research, NIID. The marmosets were housed in cages [39 cm (W)Â55 cm (D)Â70 cm (H)], in rooms that only housed marmosets. The environment was controlled, and machinery noise and barking by dogs were avoided to reduce stress. The animal facility in NIID was also tightly controlled and monitored for infectious diseases and vectors. The marmosets were fed twice a day with a standard marmoset diet (Clea New World Monkey Diet, CMS-1M, CLEA, Japan), supplemented with fresh fruits and recommended dietary supplements. Water was given ad libitum. Enrichment was provided in the form of space, resting perches and climbing structures, pieces of wood and a variety of foods, including sponge cakes, dried worms and dried fruits. Animals were routinely monitored daily for overall health, changes in behaviour and signs of discomfort. P/N, positive/negative; OD, optical density; positive detection of DENV IgM (P/N of !2.0) is indicated by underlining; P/N ratio is the OD value of positive sample/OD value of negative sample; *, plasma samples collected at day 14 for group C; NA, no samples collected. Due to accidental death, no samples were collected from marmoset B3 from day 4 of secondary inoculation. *Samples were collected from marmosets (groups D, E and F) on day 15 after inoculation.
All animal studies were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of the NIID, Tokyo, Japan. The study was approved by the Institutional Animal Care and Use Committee of NIID (approval no. 613006). At the NIID, all animal and infection experiments were performed according to the NIID Institutional Guidelines in addition to the guidelines of the Science Council and Japanese law. Animals were handled by experienced staff and veterinarians. Steps were taken to ensure animal welfare and avoid suffering. Sedation of marmosets for infection assay and blood sampling was performed with intramuscular ketamine hydrochloride (50 mg kg
À1
) with xylazine (3 mg kg
). P/N, positive/negative; OD, optical density; positive detection of DENV IgG (P/N of !2.0) is indicated by underlining; P/N ratio is the OD value of positive sample/OD value of negative sample; NA, no samples collected. Due to accidental death, no samples were collected from marmoset B3 from day 4 of secondary inoculation. *Samples were collected from marmosets (groups D, E and F) on day 15 after inoculation.
Vaccine and challenge of virus strains
vaccine strains were confirmed using Vero cells at Mahidol University. The candidate vaccine DENV-1 16007 PDK-13 strain, DENV-2 16681 PDK-53 strain and parent strains (DENV-1 16 007 and DENV-2 16681) were provided by Mahidol University, shipped in liquid form on dry ice to NIID, and stored at -80 C until use. Prior to vaccination, the viruses were thawed to room temperature, diluted with Eagle's essential medium (EMEM) to the appropriate concentrations (Table 2 ) and inoculated subcutaneously into marmosets. DENV-1 (Yoyogi strain and 01-44 strain, GenBank accession nos LC002828 and AB111070) and DENV-2 DHF0663 strain (GenBank accession no. AB189122) were used for animal challenge studies and plaque-reduction neutralizing tests (PRNTs) [23] . The clinically isolated DENV-1 (Yoyogi strain and 01-44 strain) and DENV-2 DHF0663 strains were used within four passages of cell culture. Clinically isolated viruses were chosen by the plaque-forming phenotype. Culture supernatant from infected BHK cells was centrifuged at 800 g for 5 min to remove cell debris and stored at -80 C until use [23] .
Animal study design A total of 23 marmosets were used in this study. All marmosets were adult marmosets, of an age range of 4-6 years. The marmosets were a donation from Clea Japan, Inc.
(Tokyo, Japan). The marmosets were housed at the Division of Experimental Animal Research, NIID, Japan. All animals were overall in good health and negative for anti-DENV antibodies prior to the infection experiments.
Sixteen marmosets (A1-4, B1-4, D1-4 and E1-4) were used in the initial experiment (experiment 1). The animals were split into groups of four that received 10 4 p.f.u. of DENV-1 and DENV-2 vaccine strains (marmosets A1, A2, A3 and A4; marmosets D1, D2, D3 and D4), and 10 4 p.f.u. of DENV-1 and DENV-2 parent strains (marmosets B1, B2, B3 and B4; marmosets E1, E2, E3 and E4). Virus (1.0 ml) was administered subcutaneously on the upper back. Anti-coagulated EDTA whole blood (1.0 ml) obtained from the femoral vein of the marmosets at 3 days prior to infection and on days 0, 2, 4, 7, 10, 14 and 15 was then centrifuged at 2000 g for 10 min. Plasma samples were stored at -80 C until use.
At 6 months after the first administration, the immunized animals were challenged with 10 5 p.f.u. of clinically isolated DENV-1 (Yoyogi strain). Similarly, at 9 months after the first inoculation with DENV-2, 12 marmosets were inoculated with DENV-2 DHF0663 strain. In addition, seven DENV seronegative marmosets (C1, C2, C3, F1, F2, F3 and F4) were inoculated with 10 5 p.f.u. of the DENV-1 Yoyogi strain (marmosets C1, C2 and C3), and 10 5 p.f.u. of the DENV-2 DHF0663 strain (marmosets F1, F2, F3 and F4). Blood samples (1.0 ml) were obtained from the femoral vein 3 days prior to infection, and on days 0, 2, 4, 7, 10, 14 and 15. After DENV administration, the marmosets were observed daily for their overall condition. NA no samples collected; the limit of the test was PRNT <10. 
Plasma viral genome levels and viraemia
The viral genome levels in the plasma samples were determined after virus inoculation using quantitative TaqMan realtime reverse transcriptase-PCR (TaqMan RT-PCR) [22, 61] . quantitative RT-PCR assays were prepared from synthesized RNA from cDNA clones [22] . A standard using a 5-point 10-fold serial dilution of standard cDNA (10 8 genome copies to 10 4 genome copies) in each reaction was used in duplicate for quantification of viral genome levels. The viral genome levels determined were expressed as log 10 genome copies ml
À1
. Plasma samples were then tested using the plaque assay to determine the viraemia levels. BHK cells were used in the plaque assay [24] . The plasma samples were serially diluted 10-fold from 1 : 10 1 to 1 : 10 6 with EMEM (Sigma) supplemented with 10 % foetal bovine serum (FBS). Fifty microlitres of diluted serum samples was inoculated onto BHK cell monolayers in 12-well plates. The plates were incubated for 1 h at 37 C in 5 % CO 2 . After virus absorption, the cells were overlaid with maintenance medium containing 1 % methylcellulose (Wako Pure Chemical Industry, Osaka, Japan). The plates were incubated at 37 C in 5 % CO 2 until visible plaques could be observed (5-7 days of incubation). The cells were fixed with formaldehyde, stained with methylene blue and washed with water. Assays were conducted in duplicate. Viral titres were expressed as p.f.u. per millilitre (p.f.u. ml À1 ), using the following formula: (number of plaques per well) Â (dilution)/(inoculum volume).
DENV NS1 antigen levels
Detection of NS1 antigen levels in marmoset plasma samples was performed using an NS1 antigen ELISA kit (Platelia, Bio-Rad Laboratories, Marnes-la-Coquette, France). In brief, 25 µl of plasma sample was added to 75 µl of sample diluent and added to the wells. A total of 100 µl of diluted HRP-conjugated anti-NS1 monoclonal antibody was then added to the wells. The plate was then incubated for 90 min at 37 C. The wells were then washed, 160 µl of tetramethylbenzidine (TMB) substrate was added to each well and the plate was further incubated for 30 min at room temperature. The reaction was terminated with 100 µl of 1 N H 2 SO 4 . The optical density (OD) of the samples was determined with a spectrophotometer at wavelengths of 450 nm. Positive/negative (P/N) ratios of <2 and !2 were considered to be negative and positive, respectively [23] .
Antibody response
To determine the DENV-specific antibody levels, anti-DENV IgM and IgG antibody ELISA assays were performed. DENV-specific IgM antibodies were detected by Dengue fever IgM capture ELISA (Focus) and DENV-specific IgG antibodies were examined by Dengue IgG indirect ELISA (PanBio) in accordance with the manufacturer's instructions. The P/N ratio was calculated using the formula: OD of the test sample divided by the OD of a negative sample. Plasma samples collected from three DENV-naïve marmosets were used as the negative samples. P/N ratios of <2 and !2 were considered to be negative and positive, respectively. All ELISAs were conducted in duplicate [24] .
Plasma samples were heat-treated at 56 C for 30 min to inactivate the complement factors. Briefly, heat-inactivated plasma samples were serially diluted twofold from 1 : 5 to 1 : 2560 with EMEM supplemented with 10 % FBS. The virus-antibody mixture was prepared by mixing 25 µl of DENV-1 01-44 strain and DENV-2 DHF0663 strain at titres of 2000 p.f.u. ml À1 (50 p.f.u. in 25 µl) with 25 µl of serially diluted plasma samples to make up a final plasma dilution of 1 : 10 to 1 : 5120. The controls were prepared by mixing 25 µl of DENV at titres of 2000 p.f.u. ml À1 with 25 µl of EMEM supplemented with 10 % FBS. The virus-plasma sample mixture was incubated at 37 C for 1 h. Fifty microlitres of virus-plasma sample mixture was inoculated onto BHK and FcgR-expressing BHK cell monolayers in 12-well plates at 37 C for 60 min. Plates were then overlaid with methylcellulose (Wako) in EMEM (Nissui), supplemented with 2 % FBS overlay. After 5-7 days of incubation, cells were fixed with formaldehyde and stained with methylene blue. A neutralizing assay was performed in plasma samples obtained on days with increased levels of DENV-specific IgG antibody. The neutralization titre was expressed as the maximum dilution of the plasma sample that yielded a >50 % plaque reduction in the virus inoculum in comparison to the control, calculated from !2 replicates.
Statistical analysis
Statistical analysis was performed using the statistical package in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and Kaleidagraph software (Synergy Software, Philadelphia, PA, USA). Non-parametric Kruskal-Wallis and Mann-Whitney tests were used to compare values between the marmoset groups. A P-value of <0.05 was considered to be a statistically significant difference. The results were expressed as the mean value of each group.
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